High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali
Author(s) -
Djeneba Fofana,
C. Soulie,
Aliou Baldé,
Sidonie Lambert-Niclot,
Mariam Sylla,
Zaïna Ait-Arkoub,
Fodié Diallo,
B. Sangaré,
Mohamed Cissé,
I. A. Maiga,
Slim Fourati,
Ousmane Koita,
Vincent Cálvez,
AnneGeneviève Marcelin,
Almoustapha Issiaka Maïga
Publication year - 2014
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dku153
Subject(s) - rilpivirine , etravirine , medicine , reverse transcriptase inhibitor , viral load , resistance mutation , virology , drug resistance , lamivudine , reverse transcriptase , regimen , nucleoside reverse transcriptase inhibitor , genotype , dolutegravir , coinfection , efavirenz , gastroenterology , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , virus , polymerase chain reaction , hepatitis b virus , microbiology and biotechnology , biochemistry , gene
In resource-limited settings, few data are available on virological failure after long-term first-line antiretroviral therapy. This study characterized the genotypic resistance patterns at the time of failure after at least 36 months of a first-line regimen in Mali, West Africa.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom